Menin inhibitors constitute a novel class of agents targeting the underlying biology of
nucleophosmin (NPM1) mutant and KMT2A (formerly known as MLL1) rearranged (KMT2Ar) …

To the Editor: Acute lymphoblastic leukemia (ALL) bearing the KMT2A-rearrangement is a
high-risk genomic subgroup, characterized by chemotherapy-resistance and a propensity for …

PURPOSE Despite recent advances in adapting the intensity of treatment for older patients
with ALL, current protocols are associated with high rates of early deaths, treatment-related …

Simple Summary Pediatric patients with relapsed or refractory acute myeloid leukemia
(AML) have poor survival with current therapy. Venetoclax is a small molecule inhibitor that …

Abstract KMT2A-rearranged (KMT2A-r) B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) is widely recognized as a high-risk leukemia in both children and adults. However …

Background Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL)
experienced poor outcomes with intensive chemotherapy. This mature analysis explores the …

The outcome of B-cell acute lymphoblastic leukemia (B-ALL) has improved over time with
the incorporation of multi-agent chemotherapy in the treatment landscape as well as the …

Objective There are significant disparities in outcomes among Hispanic patients with acute
lymphoblastic leukemia (ALL). Recent studies have demonstrated favorable outcomes of …

Background: Acute myeloid leukemia (AML) is a disease of the hematopoietic system that
remains a therapeutic challenge despite advances in our understanding of the underlying …

Recent advances have included insights into the clinical value of genomic abnormalities in
acute myeloid leukemia (AML) and consequently the development of numerous targeted …